![]() ![]() Irrespective of follow-up timing, being older was associated with lower nAB for participants who received BNT162b2 and but not for those who received mRNA-1273. At the 6-month time point, nABs to were significantly higher than nABs to BNT162b2 and equivalent to mRNA-1273. ![]() Over 6 months of follow-up, nABs declined in recipients of BNT162b2 and mRNA-1273, while nABs in recipients of showed a significant increase. Participants completed questionnaires and underwent blood draws prior to vaccination, 1 month, and 6 months after the vaccination series, and neutralizing antibody (nAB) titers at 1- and 6-months post vaccination were quantified using a high-throughput pseudovirus assay. This was a head-to-head comparison study following 498 healthy, community volunteers who received the BNT162b2 (n = 287), mRNA-1273 (n = 149), and (n = 62). As concerns related to the COVID-19 pandemic continue, it is critical to understand the impact of vaccination type on neutralizing antibody response durability as well as to identify individual difference factors related to decline in neutralization. ![]()
0 Comments
Leave a Reply. |